



Deutsche Gesellschaft für
Psychiatrie und Psychotherapie,
Psychosomatik und
Nervenheilkunde e.V.



Deutsches Netzwerk
Versorgungsforschung e.V.



DEUTSCHE GESELLSCHAFT
FÜR SOZIALMEDIZIN
UND PRÄVENTION

Save the date: Vortrag am Welttag für Seelische Gesundheit, 10. Oktober, via Zoom

Liebe Kolleginnen, liebe Kollegen,

der Fachbereich Public Mental Health der DGPH, die Arbeitsgruppe Public Mental Health der DGSMF und das Referat Psychosoziale Versorgungsforschung und Public Mental Health der DGPPN laden Sie ein zu einem Vortrag am Welttag der Seelischen Gesundheit, **Donnerstag, 10. Oktober, ab 15:00 Uhr** via Zoom:

Kelly K. Anderson, PhD

Canada Research Chair in Public Mental Health
Research

Associate Professor

Department of Epidemiology & Biostatistics

Department of Psychiatry

Schulich School of Medicine & Dentistry

Western University

Email: kelly.anderson@schulich.uwo.ca



Population-level impacts of cannabis legalization on psychotic disorders in Canada: What do we know so far?

Biography

Dr. Kelly Anderson is a Canada Research Chair in Public Mental Health Research, an Associate Professor in the Department of Epidemiology and Biostatistics at Western University, and a Senior Adjunct Scientist at ICES (formerly the Institute for Clinical

Evaluative Sciences). She received her PhD in Epidemiology from McGill University, and completed a post-doctoral fellowship at the Centre for Addiction and Mental Health in Toronto. Her research interests lie at the intersection of population health and health services research. She is interested in the risk, course, and outcome of mental illness for different population groups, as well as in the social determinants of health service access and utilization. She has a particular interest in the mental health of adolescents and young adults, and her research to date has typically focused on first-episode psychosis and early intervention services.

Summary

Cannabis has been implicated as a causal factor in the onset and persistence of psychotic disorders. Canada legalized the non-medical use of cannabis in October 2018, despite concerns that increases in cannabis use following legalization may have consequences for the frequency and health services utilization for psychotic disorders at the population level. This presentation will review findings from a series of population-based studies focused on: (i) changes in the incidence and health service use for psychotic disorders during a post-legalization period with strict limits on cannabis retailers and product types; (ii) the impact of cannabis retailer proximity on service use for psychotic disorders; and (iii) the impacts of widespread cannabis commercialization, which removed market restrictions, on use of acute mental health services for psychotic disorders.

Über Zoom teilnehmen

Donnerstag, 10. Oktober 2024, 15 – 16 Uhr

Nehmen Sie per Computer, Tablet oder Smartphone teil:

<https://zi-mannheim-de.zoom.us/j/67644769386?pwd=RW5CQUllazh5K0p3dDV4QnEwdUFRdz09>

Meeting ID: 676 4476 9386

Zugangscode: 407194

Sie können sich auch per Telefon einwählen:

+49 69 3807 9883 Deutschland

+49 69 3807 9884 Deutschland

+49 69 5050 0951 Deutschland

+49 69 5050 0952 Deutschland

+49 695 050 2596 Deutschland

+49 69 7104 9922 Deutschland

Schnelleinwahl mobil:

+496938079883,,67644769386#,,,,*407194# Germany

+496938079884,,67644769386#,,,,*407194# Germany

Wir freuen uns auf einen anregenden Vortrag und ein großes Publikum!

Ihr Organisationsteam

Prof. Dr. Ulrich Reininghaus, Mannheim

Prof. Dr. med. Steffi Riedel-Heller, Leipzig

Prof. Dr. Georg Schomerus, Leipzig